Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,658,365 papers from all fields of science
Search
Sign In
Create Free Account
pan-RAF Kinase Inhibitor TAK-580
Known as:
MLN-2480
, TAK580
, MLN2480
Expand
An orally available inhibitor of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Applying support-vector machine learning algorithms toward predicting host-guest interactions with cucurbit[7]uril.
A. Tabet
,
Thomas Gebhart
,
+8 authors
O. Scherman
Physical chemistry chemical physics : PCCP
2020
Corpus ID: 220075702
Machine learning is a valuable tool in the development of chemical technologies but its applications into supramolecular…
Expand
2019
2019
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases
Gautham Gampa
,
Minjee Kim
,
+4 authors
W. Elmquist
The Journal of Pharmacology and Experimental…
2019
Corpus ID: 58608523
Targeted inhibition of RAF and MEK by molecularly targeted agents has been employed as a strategy to block aberrant mitogen…
Expand
2018
2018
LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY
K. Wright
,
M. Zimmerman
,
Eli J. Fine
,
Tristan Aspri
,
M. Kieran
,
S. Chi
2018
Corpus ID: 80635306
2017
2017
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas
Yu Sun
,
J. Alberta
,
+19 authors
C. Stiles
Neuro-oncology
2017
Corpus ID: 3951444
Background Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade…
Expand
2015
2015
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in…
A. Olszanski
,
M. Middleton
,
+6 authors
T. Macarulla
2015
Corpus ID: 77375762
TPS2609 Background: Signaling hyperactivation secondary to MAPK pathway aberrations are common. RAF kinases play key roles in the…
Expand
2014
2014
364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma
M. Middleton
,
D. Rasco
,
+11 authors
R. Gonzalez
2014
Corpus ID: 75517057
2014
2014
162 Drug–drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data
S. Balani
,
A. Bulychev
,
+10 authors
S. Prakash
2014
Corpus ID: 71353125
2014
2014
495 Divergent androgen regulation of UPR pathways drives prostate cancer
Y. J. Arnoldussen
,
M. Storm
,
+12 authors
F. Saatcioglu
2014
Corpus ID: 71915259
2013
2013
MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.
D. Rasco
,
A. Olszanski
,
+8 authors
V. Bozon
2013
Corpus ID: 78692905
2547 Background: MLN2480 is an investigational pan-RAF kinase inhibitor. In vivo, MLN2480 showed antitumor activity in melanoma…
Expand
2013
2013
Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models…
E. Cunniff
,
Julie Zhang
,
+17 authors
K. Galvin
2013
Corpus ID: 79452221
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE